The approval was based on data from the double-blind, placebo-controlled ClarIDHy study. The Food and Drug Administration (FDA) has approved Tibsovo ® (ivosidenib) for the treatment of adult patients ...

BOSTON, May 5, 2021 /PRNewswire/ -- Servier Pharmaceuticals, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and ...

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today ...

CAMBRIDGE, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced ...

Please provide your email address to receive an email when new articles are posted on . Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated ...

ChatGPT said: The intrahepatic cholangiocarcinoma (iCCA) pipeline is growing steadily, with over 18 companies focused on targeted and immunotherapeutic strategies. Key advances include FGFR2 fusions, ...

A drug used to treat a form of adult leukemia has shown efficacy in a form of bile duct cancer that has no approved treatments. On Monday, Cambridge, Massachusetts-based Agios Pharmaceuticals ...

The evaluation committee considered evidence submitted by Servier, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for ...

The U.S. Food and Drug Administration (FDA) has granted pre-market approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients with isocitrate ...

CAMBRIDGE, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced ...

CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today ...